FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a heterocyclic compound of formula (I), where
is:
is:
,
and X is CH or N; or a pharmaceutically acceptable salt thereof. Invention also relates to specific compounds, a pharmaceutical composition and an FXIa inhibitor, based on the compound of formula (I), use of said compounds and a method of preventing and / or treating thromboembolic disease.
EFFECT: technical result is obtaining a novel heterocyclic compound having FXIa inhibition effect.
14 cl, 3 dwg, 4 tbl, 46 ex
или - or
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS | 2012 |
|
RU2630677C2 |
| SUBSTITUTED PYRROLIDINES AS XIa FACTOR INHIBITORS FOR THROMBOEMBOLIC DISEASES TREATMENT | 2013 |
|
RU2636050C2 |
| XIA FACTOR INHIBITORS | 2016 |
|
RU2728783C2 |
| SUBSTITUTED OXOPYRIDINE DERIVATIVE | 2019 |
|
RU2792645C2 |
| PYRROLIDINE-2-ONES AS INHIBITORS OF XA FACTOR | 2002 |
|
RU2318807C2 |
| XIa FACTOR INHIBITORS | 2016 |
|
RU2712268C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2015 |
|
RU2733405C2 |
| IMIDAZOLE DERIVATIVES ACTIVE TO CB1 RECEPTOR | 2005 |
|
RU2377238C2 |
| 1,4 THIAZEPINES/SULPHONES AS BACE1 AND/OR BACE2 INHIBITORS | 2012 |
|
RU2600931C2 |
| 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-RICH REPEATING KINASE 2 (LRRK2) FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2647849C2 |
